Progress in translational research on immunotherapy for osteosarcoma

doi:10.3969/j.issn.1674-8115.2024.07.002

Abstract

Abstract:

Osteosarcoma is a common primary malignant bone tumor in adolescents and children, characterized by a high recurrence rate and metastasis, making its treatment extremely challenging. Traditional treatment modalities, including surgery, radiation therapy, and chemotherapy, can alleviate symptoms to some extent, but improving long-term survival rates remains a pressing issue. With the continuous development of immunotherapy, breakthroughs have been made in the research of tumor immune microenvironment and the application of immunotherapy in recent years, providing new perspectives and strategies for osteosarcoma treatment. Currently, immunotherapy strategies include tumor vaccines, targeted cytokines, immune checkpoint inhibition, adoptive cell therapy, combination therapy, etc., significantly enhancing patient immune responses from the aspects of boosting immunity, overcoming immune tolerance, and preventing immune evasion, thereby effectively improving the patients′ survival rates and prognosis. This review aims to systematically introduce the immune microenvironment of osteosarcoma and discuss the latest advances in immunotherapy in clinical translational research of osteosarcoma. By deeply understanding the immune characteristics of osteosarcoma and corresponding treatment methods, it is hopeful to provide more effective strategies for personalized treatment, contributing to the improvement of the patients′ survival rates and prognosis.

Key words: osteosarcoma, tumor immune microenvironment (TIME), immunotherapy, clinical translation

CLC Number:

R738.1

HU Fei, CAI Xiaohan, CHENG Rui, JI Shiyu, MIAO Jiaxin, ZHU Yan, FAN Guangjian. Progress in translational research on immunotherapy for osteosarcoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(7): 814-821.

TrendMD

References 69

1	ZHAO X, WU Q R, GONG X Q, et al. Osteosarcoma: a review of current and future therapeutic approaches[J]. Biomed Eng Online, 2021, 20(1): 24.
2	BERNTHAL N M, FEDERMAN N, EILBER F R, et al. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma[J]. Cancer, 2012, 118(23): 5888-5893.
3	XU Y, SHI F Q, ZHANG Y T, et al. Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors[J]. Int J Cancer, 2024, 154(2): 226-240.
4	MOUKENGUE B, LALLIER M, MARCHANDET L, et al. Origin and therapies of osteosarcoma[J]. Cancers, 2022, 14(14): 3503.
5	ZHU T Y, HAN J, YANG L, et al. Immune microenvironment in osteosarcoma: components, therapeutic strategies and clinical applications[J]. Front Immunol, 2022, 13: 907550.
6	ZHOU Y, YANG D, YANG Q C, et al. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma[J]. Nat Commun, 2020, 11(1): 6322.
7	CERSOSIMO F, LONARDI S, BERNARDINI G, et al. Tumor-associated macrophages in osteosarcoma: from mechanisms to therapy[J]. Int J Mol Sci, 2020, 21(15): 5207.
8	刘净峰, 徐鸿锋, 刘巍峰. 骨肉瘤驱动基因与免疫微环境及靶向治疗的研究进展[J]. 中国骨与关节杂志, 2024, 13(5): 390-395.
	LIU J F, XU H F, LIU W F. Research advances on osteosarcoma driver genes, immune microenvironment, and targeted therapy[J]. Chinese Journal of Bone and Joint, 2024, 13(5): 390-395.
9	HUANG Q S, LIANG X, REN T T, et al. The role of tumor-associated macrophages in osteosarcoma progression-therapeutic implications[J]. Cell Oncol, 2021, 44(3): 525-539.
10	TIAN H L, CAO J J, LI B W, et al. Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment[J]. Bone Res, 2023, 11(1): 11.
11	HOU C H, LU M, LEI Z X, et al. HMGB1 positive feedback loop between cancer cells and tumor-associated macrophages promotes osteosarcoma migration and invasion[J]. Lab Invest, 2023, 103(5): 100054.
12	WOLF-DENNEN K, GORDON N, KLEINERMAN E S. Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions[J]. Oncoimmunology, 2020, 9(1): 1747677.
13	CHENG Z H, WANG L Q, WU C H, et al. Tumor-derived exosomes induced M2 macrophage polarization and promoted the metastasis of osteosarcoma cells through Tim-3[J]. Arch Med Res, 2021, 52(2): 200-210.
14	ANAND N, PEH K H, KOLESAR J M. Macrophage repolarization as a therapeutic strategy for osteosarcoma[J]. Int J Mol Sci, 2023, 24(3): 2858.
15	RAGGI C, MOUSA H S, CORRENTI M, et al. Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies[J]. Oncogene, 2016, 35(6): 671-682.
16	LIN J T, XU A K, JIN J K, et al. MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression[J]. Oncoimmunology, 2022, 11(1): 2024941.
17	KALLURI R, LEBLEU V S. The biology,function,and biomedical applications of exosomes[J]. Science, 2020, 367(6478): eaau6977.
18	ZHANG L, YU D H. Exosomes in cancer development, metastasis, and immunity[J]. Biochim Biophys Acta Rev Cancer, 2019, 1871(2): 455-468.
19	WANG J, ZHANG H L, SUN X, et al. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients[J]. J Nanobiotechnology, 2020, 18(1): 151.
20	PU F F, CHEN F X, ZHANG Z C, et al. Information transfer and biological significance of neoplastic exosomes in the tumor microenvironment of osteosarcoma[J]. Onco Targets Ther, 2020, 13: 8931-8940.
21	TANG J X, HE J Y, FENG C Y, et al. Exosomal miRNAs in osteosarcoma: biogenesis and biological functions[J]. Front Pharmacol, 2022, 13: 902049.
22	DYSON K A, STOVER B D, GRIPPIN A, et al. Emerging trends in immunotherapy for pediatric sarcomas[J]. J Hematol Oncol, 2019, 12(1): 78.
23	ZHONG R, LING X, CAO S, et al. Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers[J]. ESMO Open, 2022, 7(1): 100334.
24	YU J F, SUN H, CAO W J, et al. Research progress on dendritic cell vaccines in cancer immunotherapy[J]. Exp Hematol Oncol, 2022, 11(1): 3.
25	ASSI T, WATSON S, SAMRA B, et al. Targeting the VEGF pathway in osteosarcoma[J]. Cells, 2021, 10(5): 1240.
26	DUFFAUD F, MIR O, BOUDOU-ROUQUETTE P, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study[J]. Lancet Oncol, 2019, 20(1): 120-133.
27	DAVIS L E, BOLEJACK V, RYAN C W, et al. Randomized double-blind phase Ⅱ study of regorafenib in patients with metastatic osteosarcoma[J]. J Clin Oncol, 2019, 37(16): 1424-1431.
28	DUFFAUD F, BLAY J Y, LE CESNE A, et al. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase Ⅱ study[J]. Br J Cancer, 2023, 129(12): 1940-1948.
29	TIAN Z C, WANG J Q, GE H. Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signalling[J]. J Orthop Translat, 2020, 22: 132-141.
30	LIU K S, REN T T, HUANG Y, et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma[J]. Cell Death Dis, 2017, 8(8): e3015.
31	XIE L, XU J, SUN X, et al. Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase Ⅱ clinical trial[J]. Oncologist, 2019, 24(7): e542-e550.
32	ZHANG X, PAN Q Z, PENG R Q, et al. A phase Ⅱ study of surufatinib in patients with osteosarcoma and soft tissue sarcoma who have experienced treatment failure with standard chemotherapy[J]. J Clin Oncol, 2023, 41(16_suppl): e23540.
33	YU L F, FAN G T, WANG Q Y, et al. In vivo self-assembly and delivery of VEGFR2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy[J]. Cell Death Dis, 2023, 14(9): 626.
34	HAVEL J J, CHOWELL D, CHAN T A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy[J]. Nat Rev Cancer, 2019, 19(3): 133-150.
35	YI M, NIU M K, XU L P, et al. Regulation of PD-L1 expression in the tumor microenvironment[J]. J Hematol Oncol, 2021, 14(1): 10.
36	HASHIMOTO K, NISHIMURA S, AKAGI M. Characterization of PD-1/PD-L1 immune checkpoint expression in osteosarcoma[J]. Diagnostics, 2020, 10(8): 528.
37	TODA Y, KOHASHI K, YAMADA Y, et al. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions[J]. J Cancer Res Clin Oncol, 2020, 146(10): 2607-2620.
38	DHUPKAR P, GORDON N, STEWART J, et al. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases[J]. Cancer Med, 2018, 7(6): 2654-2664.
39	ZHANG M, CHEN L, LI Y, et al. PD‑L1/PD‑1 axis serves an important role in natural killer cell‑induced cytotoxicity in osteosarcoma[J]. Oncol Rep, 2019, 42(5): 2049-2056.
40	BOYE K, LONGHI A, GUREN T, et al. Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial[J]. Cancer Immunol Immunother, 2021, 70(9): 2617-2624.
41	WEN Y, TANG F, TU C Q, et al. Immune checkpoints in osteosarcoma: recent advances and therapeutic potential[J]. Cancer Lett, 2022, 547: 215887.
42	XIE L, XU J, SUN X, et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial[J]. J Immunother Cancer, 2020, 8(1): e000798.
43	SZNOL M, MELERO I. Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy[J]. Ann Oncol, 2021, 32(3): 295-297.
44	ROY D, GILMOUR C, PATNAIK S, et al. Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors[J]. Front Immunol, 2023, 14: 1264327.
45	BAGCHI S, YUAN R, ENGLEMAN E G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance[J]. Annu Rev Pathol, 2021, 16: 223-249.
46	YUAN J H, JIA J Y, WU T L, et al. Long intergenic non-coding RNA DIO3OS promotes osteosarcoma metastasis via activation of the TGF-β signaling pathway: a potential diagnostic and immunotherapeutic target for osteosarcoma[J]. Cancer Cell Int, 2023, 23(1): 215.
47	XIE L, CHEN C L, LIANG X, et al. Expression and clinical significance of various checkpoint molecules in advanced osteosarcoma: possibilities for novel immunotherapy[J]. Orthop Surg, 2023, 15(3): 829-838.
48	ZHANG Y M, GAN W Y, RU N, et al. Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma[J]. J Bone Oncol, 2023, 40: 100481.
49	SCHULTZ L. Chimeric antigen receptor T cell therapy for pediatric B-ALL: narrowing the gap between early and long-term outcomes[J]. Front Immunol, 2020, 11: 1985.
50	LI S Z, ZHANG H, SHANG G N. Current status and future challenges of CAR-T cell therapy for osteosarcoma[J]. Front Immunol, 2023, 14: 1290762.
51	CORTI C, VENETIS K, SAJJADI E, et al. CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress[J]. Expert Opin Investig Drugs, 2022, 31(6): 593-605.
52	KACZANOWSKA S, MURTY T, ALIMADADI A, et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy[J]. Cancer Cell, 2024, 42(1): 35-51.e8.
53	ZHU J W, SIMAYI N, WAN R X, et al. CAR T targets and microenvironmental barriers of osteosarcoma[J]. Cytotherapy, 2022, 24(6): 567-576.
54	MENSALI N, KÖKSAL H, JOAQUINA S, et al. ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma[J]. Nat Commun, 2023, 14(1): 3375.
55	MOONAT H, HUANG G X, DHUPKAR P, et al. Combination of interleukin-11Rα chimeric antigen receptor T-cells and programmed death-1 blockade as an approach to targeting osteosarcoma cells in vitro[J]. Cancer Transl Med, 2017, 3(4): 139.
56	LUSSIER D M, JOHNSON J L, HINGORANI P, et al. Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma[J]. J Immunother Cancer, 2015, 3: 21.
57	D'ANGELO S P, MAHONEY M R, VAN TINE B A, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials[J]. Lancet Oncol, 2018, 19(3): 416-426.
58	KAWANO M, ITONAGA I, IWASAKI T, et al. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma[J]. Oncol Rep, 2013, 29(3): 1001-1006.
59	KRUPKA C, KUFER P, KISCHEL R, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism[J]. Leukemia, 2016, 30(2): 484-491.
60	SUN C, DOTTI G, SAVOLDO B. Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies[J]. Blood, 2016, 127(26): 3350-3359.
61	WANG Z, LI B H, REN Y Q, et al. T-cell-based immunotherapy for osteosarcoma: challenges and opportunities[J]. Front Immunol, 2016, 7: 353.
62	CHAPUIS A G, ROBERTS I M, THOMPSON J A, et al. T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression[J]. J Clin Oncol, 2016, 34(31): 3787-3795.
63	CURRAN M A, MONTALVO W, YAGITA H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors[J]. Proc Natl Acad Sci U S A, 2010, 107(9): 4275-4280.
64	YU A L, GILMAN A L, OZKAYNAK M F, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma[J]. N Engl J Med, 2010, 363(14): 1324-1334.
65	ZHU W H, MAO X Z, WANG W C, et al. Anti-ganglioside GD2 monoclonal antibody synergizes with cisplatin to induce endoplasmic reticulum-associated apoptosis in osteosarcoma cells[J]. Pharmazie, 2018, 73(2): 80-86.
66	THANINDRATARN P, DEAN D C, NELSON S D, et al. Advances in immune checkpoint inhibitors for bone sarcoma therapy[J]. J Bone Oncol, 2019, 15: 100221.
67	YAMADA N, HATA M, OHYAMA H, et al. Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model[J]. Tumour Biol, 2009, 30(4): 176-184.
68	HE X J, LIN H Q, YUAN L, et al. Combination therapy with L-arginine and α-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice[J]. Cancer Biol Ther, 2017, 18(2): 94-100.
69	KAWANO M, TANAKA K, ITONAGA I, et al. Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma[J]. Oncol Lett, 2016, 11(3): 2169-2175.

[1]	ZHOU Haixia, ZHANG Jing. Research progress of m⁶A methylation modification in regulating tumor immunity [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(1): 137-144.
[2]	WEI Lanyi, XUE Xiaochuan, CHEN Junjun, YANG Quanjun, WANG Mengyue, HAN Yonglong. Research progress of tumor-associated macrophages in immune microenvironment and targeted therapy of osteosarcoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 624-630.
[3]	LU Yu, WANG Hao, BA Qian. Role of gut microbiota in hepatocellular carcinoma: cancer occurrence, progresses and treatments [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(7): 939-944.
[4]	Jing-wei LI, Li-wen WANG, Ling-xi JIANG, Qian ZHAN, Hao CHEN, Bai-yong SHEN. Review of immunosuppressive tumor microenvironment of pancreatic cancer [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1103-1108.
[5]	Xu-xin-yi LING, Yao ZHANG, Hua ZHONG. Research progress in screening non-small cell lung cancer patients who will benefit from immunotherapy [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1114-1119.
[6]	Paerhati NADINA, Yan YAN, Qian-ji CHE, Jing LUO, Xin-nan LIU, Bin LI. Application and prospect of chimeric antigen receptor-modified T cell therapy for glioblastoma [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(7): 982-986.
[7]	Yun-fang MA, Li-na PAN, Zhen LI, Bei-li GAO, Jia-an HU, Zhi-hong XU. Exploratory study on downregulation of PD-L1 in KRAS G12V-mutant non-small cell lung cancer cells by selumetinib [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(6): 741-748.
[8]	HE Chun-ming, YIN Hang, ZHENG Jia-jie, TANG Jian, FU Yu-jie, ZHAO Xiao-jing. Immunotherapy for lung cancer: immunosuppressive cells and intrapulmonary immunity [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(8): 1137-1142.
[9]	LIU Jie, QIU Xiao-chun. Research hotspots and trends of breast cancer stem cells [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(7): 881-888.
[10]	DAI Fei, WEI Jin-jin, TANG Xin-yue, CHEN Zheng, LIN Lin. Effect of sublingual immunotherapy on functions of effector T cells and regulatory T cells [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(5): 626-632.
[11]	ZHAO Yi-si1, YU Ying-xi1, LIN Shi-hui2, XU Fang1, 2. Advances in the study of T cell immunity in invasive fungal infections secondary to sepsis [J]. , 2019, 39(11): 1325-.
[12]	LI Xia-yi, ZHENG Lei-zhen. Application of programmed cell death protein 1/programmed death-ligand 1 blockade in advanced gastric cancer treatment [J]. , 2018, 38(10): 1259-.
[13]	XIA Li, WANG Yue-ying . Chimeric antigen receptor T-cell immunotherapy and its applications in hematological malignancies immunotherapy [J]. , 2017, 37(6): 822-.
[14]	MA Cai-xia, LU Mei-fang, GE Li-ping, et al. Clinical evaluation of sublingual allergen specific immunotherapy in treatment to children with bronchial asthma and allergic rhinitis [J]. , 2014, 34(6): 873-.
[15]	LU Jiang-wen, LI Jia-rui. Research status and prospect in dendritic cell vaccine for ovarian cancer [J]. , 2014, 34(1): 113-.